| 2026-08-06 | Deck | Corporate Presentation August 2026 |
| 2026-08-04 | Press release | Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-28 | Press release | Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 |
| 2026-07-14 | Press release | 07.14.26 Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event – Expands pipeline with SND |
| 2026-07-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-11 | Press release | 06.11.26 Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EH |
| 2026-06-11 | Press release | 06.11.26 Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine |
| 2026-06-10 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-10 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-04 | Proxy | SCHEDULE 14A Proxy Statement |
| 2026-06-04 | Press release | 06.04.26 Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes NEW YORK, (GLOBE |
| 2026-06-04 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-02 | Press release | 06.02.26 Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Tra |
| 2026-06-01 | Press release | 06.01.26 Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 NEW YORK, J |
| 2026-05-20 | Press release | 05.20.26 Syndax Announces Participation in Upcoming Investor Conferences NEW YORK, (GLOBE NEWSWIRE) - Synd |
| 2026-05-12 | Press release | 05.12.26 Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhib |
| 2026-04-30 | Proxy | SCHEDULE 14A Proxy Statement |
| 2026-04-30 | Press release | Syndax Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-04-30 | Deck | First Quarter 2026 Financial Results and Business Update |
| 2026-04-30 | Proxy | Definitive proxy statement |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-24 | Press release | Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 |
| 2026-03-02 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-26 | Deck | Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-26 | Press release | Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Press release | 02.23.26 Syndax Announces Participation in March Investor Conferences NEW YORK, (GLOBE NEWSWIRE) - Syndax |
| 2026-02-19 | Press release | Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 |
| 2026-02-05 | Press release | 02.05.26 Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit NEW YORK |
| 2026-01-12 | Deck | J.P. Morgan 44th Annual Healthcare Conference January 12, 2026 |
| 2026-01-12 | Press release | 01.12.26 Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morg |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-07 | Press release | 01.07.26 Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Re |
| 2026-01-05 | Press release | 01.05.26 Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference NEW YORK , (GL |
| 2025-12-19 | 8-K | Form 8-K, Item 5.03 |